Table 3 Cox regression analysis for associations of clinicopathological parameters with PFS

Age (continuous)

1.001

0.982–1.021

0.886

PSA at diagnosis (continuous)

1.021

0.864–1.473

0.378

Biopsy Gleason score

 8 vs. 6–7

1.39

0.758–2.548

0.288

 9–10 vs. 6–7

1.366

0.793–2.350

0.261

Primary treatment modality (ADT vs. ADT + Docetaxel)

0.534

0.384–0.742

0.001

0.318

0.219–0.461

0.001

Tumor volume (low vs. high)

0.376

0.263–0.537

0.001

0.383

0.264–0.556

0.001

T stage

 cT3 vs. cT2

1.392

0.916–2.115

0.121

 cT4 vs. cT2

1.244

0.813–1.903

0.315

N stage (N0 vs. N1)

0.551

0.386–0.787

0.001

0.501

0.339–0.740

0.001

NRLN metastases (absence vs. presence)

0.522

0.356–0.764

0.001

0.407

0.265–0.625

0.001

Bone metastases (absence vs. presence)

0.833

0.470–1.477

0.532

Visceral metastases (absence vs. presence)

0.38

0.227–0.635

0.001

0.346

0.196–0.613

0.001